October 2020

PIC/S Expert Circle on Quality Risk Management (QRM) webinar, hosted by Turkey / TMMDA, 24 September 2020

Geneva, 19 October 2020: On 24 September 2020 a webinar meeting of the PIC/S Expert Circle on Quality Risk Management (QRM), was hosted by the Turkish Medicines and Medical Devices Agency (TMMDA).

This PIC/S Expert Circle, currently chaired by Ireland / HPRA, has been active in developing and running advanced QRM training for GMP Inspectors for several years now to enable them to more effectively inspect the application of risk assessment and QRM during inspections in a harmonised manner. It also enables Inspectors to effectively use the PIC/S Recommendation in relation to risk-based GMP inspection planning (PI 037-1).

This webinar, which included some training aspects, was solely for GMP inspectors, and allowed to discuss updates and progress on applicable QRM guidance.

In particular, it led to important developments on:

  • The revision of the PIC/S Aide Memoire on inspecting the implementation of QRM (PI 038-1) including discussions on the revision work in progress and gathering feedback on what the revised Aide Memoire should address;
  • The QRM Curriculum and the QRM e-Module being developed for the PIC/S Inspectorates’ Academy (PIA) and how these might be used by Inspectorates;
  • The PIC/S Recommendation Paper on Evaluating and Demonstrating the Effectiveness of the Pharmaceutical Quality System (PQS) with respect to Risk-based Change Management (PI 054-1 (Draft 1)) currently being applied on a trial basis by PIC/S Participating Authorities. See also interview of the Chair of the Expert Circle on this topic in Press Release of December 2019;
  • ICH Q12 and its relevance for GMP Inspectors, in particular training under development by the PIC/S Working Group on ICH Q12 Training Materials, chaired by France / ANSM, and the value of PI 054-1 (Draft 1) in this perspective.

The webinar was attended by more than 200 inspectors from more than 50 countries / entities, including PIC/S Members, (Pre-)Applicants, Partners as well as a large number of non-PIC/S Member Medicines Regulatory Authorities, namely from Chad, Congo, Gambia, Ghana, India, Kenya, Libya, Malawi, Namibia, Philippines, Russian Federation, Sierra Leone, Somaliland, Sri Lanka, Tanzania, Tunisia, Uganda, Yemen, Zambia and Zimbabwe.

For some of these non-Members, in particular from Africa, this was the first time they were attending a PIC/S event.

In addition to its Members (53), Applicants (4), Pre-Applicants (4) and Partners (EDQM, EMA, OIE, UNICEF and WHO), PIC/S as a global organisation very much welcomes interest and opportunities for engagement with non-Member Medicines Regulatory Authorities, even if they are not yet ready to submit a PIC/S accession or pre-accession application.

This also underlines the importance of one of PIC/S most important projects, the PIC/S Inspectorates’ Academy, which is a Global Capacity and Training Initiative aiming at delivering inspection excellence through harmonised training in the field of GMP to ensure that high quality standards for medicinal products are met worldwide in the interest of public health.

For these reasons, the recording of this webinar will be made available via the PIC/S Inspectorates’ Academy to any interested non-Member Medicines Regulatory Authorities. This will include French and Portuguese language versions thanks to the good works of Oakes Group Global and their Africa-wide PIC/S Initiative (AwPI) efforts.  AwPI is an initiative independent from PIC/S that is promoting PIC/S with non-Member authorities in Africa and will be making possible the translation to French and Portuguese. Information will be posted on the PIC/S website once this is available for non-Member Medicines Regulatory Authorities.

September 2021

China / NMPA applies for PIC/S pre-accession

Geneva, 29 September 2021: On 24 September 2021, China’s National Medical Products Administration (NMPA) submitted an application for “pre-accession” to PIC/S. This is a voluntary but highly recommended assessment step that can be completed prior to submitting an application to become a PIC/S Participating Authority. The Pre-Accession Procedure provides up to 2 years to identify any gaps between PIC/S membership requirements and the system used by the interested Competent Authority. This step helps in understanding of PIC/S’ expectations in terms of membership and compliance to facilitate success in any future membership application under the PIC/S Accession Procedure.  You can find more information about the two steps in PIC/S’s Pre-Accession and Accession Procedures on our website.  As a next step, the PIC/S Committee will nominate a Rapporteur and one or several Co-Rapporteurs, who will manage and oversee NMPA’s pre-accession process.

August 2021

PIC/S Virtual Seminar 2021

Geneva, 2 August 2021: Registrations for the 2021 PIC/S Seminar on "GMP Assessment Approaches in Post COVID-19 Era" which will be hosted virtually from 9-11 November 2021 are now open (for Medicines Regulatory Authorities only). Deadline for registration is 3 October 2021.

For more information,  please contact the PIC/S Secretariat.


2021 Seminar on “GMP Assessment Approaches in Post COVID-19 Era"  

The Ministry of Food and Drug Safety (MFDS) of the Republic of Korea is pleased to announce that the 2021 PIC/S Virtual Seminar will be hosted by MFDS from 9 to 11 November 2021.

The Seminar on “GMP Assessment Approaches in Post COVID-19 Era” will consist of presentations, interactive panel discussions, and workshops for GMP Inspectors from around the world.

As the COVID-19 pandemic has put restrictions on GMP on-site inspections, various alternative GMP assessment approaches have been taken by Regulatory Authorities to ensure the quality of pharmaceuticals. As we face the post COVID-19 era, there is a need to explore the current and future status of these GMP assessment approaches. There is also a need to be prepared for the changes that will likely be seen in post COVID-19. Therefore, in this Seminar, we look forward to valuable presentations and discussions regarding different experiences in distant assessment from regulatory and industry experts; and regarding the status of GMP assessment based on reliance.

The Seminar is open to the participation of Inspectors from Medicines Regulatory Authorities around the world.

> For more information

July 2021

Adoption and Entry into force of PI 055-1 "COVID-19 Risk Assessment for Routine On-Site Inspections"

Geneva, 15 July 2021: PIC/S is pleased to announce that following its adoption by the PIC/S Committee on 30 June 2021, the guidance on “COVID-19 Risk Assessment for Routine On-Site Inspections” (PI 055-1) will enter into force on 15 July 2021. This guidance for inspectorates, which has been prepared by the PIC/S Working Group on Inspectors Safety, is available for downloading on the page “Publications”.

July 2021

Entry into Force of PI 054-1 PQS Recommendation

Geneva, 15 July 2021: PIC/S is pleased to announce the coming into force on 15 July 2021 of the PIC/S Recommendation document titled “How to Evaluate and Demonstrate the Effectiveness of the Pharmaceutical Quality System with regard to Risk-Based Change Management”, PI 054-1.  This document addresses two fundamental and inter-related elements of the PIC/S GMP Guide - PQS effectiveness and the management of changes. It provides practical guidance for GMP Inspectors in these areas, and the implementation of that guidance has the potential to ultimately lead to the more timely management of risks to product quality and patient safety, as well as better quality and manufacturing performance, continual improvement and innovation.  This serves the interest of patients and animals.

In addition to providing guidance for GMP Inspectors, the document provides the pharmaceutical industry with a ready-made solution for addressing a key aspect of ICH Q12 - the requirement to have an effective PQS that can support the risk-based management of post-approval changes when there is more flexible regulatory oversight of such changes in place.   

The input of industry representatives was considered during the development of this document and their contributions are gratefully acknowledged. 

To download this guidance (PI 054-1), please consult the page “Publications”. 

July 2021

Adoption and Entry into Force of PIC/S Guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1)

Geneva, 1 July 2021: PIC/S is pleased to announce that following adoption by the Committee on 1 June 2021, the PIC/S Guidance on Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments (PI 041-1) will enter into force on 1 July 2021. The document marks the completion of significant effort by PIC/S Participating Authorities over an extended period of collaboration to address an area of significant industry and regulatory interest. The guidance has been developed primarily for inspectors, but also serves as a valuable resource for industry to provide clarity on areas of greatest risk and regulatory expectations. The PIC/S Working Group on Data Integrity acknowledges the support from professional associations across the pharmaceutical industry who contributed to a targeted stakeholder engagement exercise in 2019. The feedback received was highly valuable in identifying opportunities to further clarify regulatory interpretations and also collate topics for future revisions.

The draft guidance was first published by PIC/S in 2016 and applied by PIC/S Participating Authorities on a trial basis. Based on Members’ comments, it was revised by the Working Group on Data Integrity and then subject to a focused stakeholder consultation on specific issues (November 2018 – March 2019). The Working Group incorporated the feedback from stakeholders and submitted the final draft to the PIC/S Committee for adoption.

The Working Group continues its data integrity activities through development of training material for the PIC/S Inspectorates’ Academy (PIA) and other inspection-related resources for inspectors within the network.

To download this guidance (PI 041-1), please consult the page “Publications”.